



Wednesday, September 4th, 2024

8.00-09.00

Registration

9.00-09.05

Opening by Arjan Griffioen (Amsterdam)

Session 1. Cancer vaccines – chair: Arjan Griffioen (Amsterdam)

9.05- 9.40

Kees Melief
(Leiden, The Netherlands)

Clinical benefit from combination of anti-HPV therapeutic vaccine and Anti-PD-1 depends on high expression of pre-treatment cancer tissue biomarker.

9.40-10.15

Inge Marie Svane
(Copenhagen, Denmark)

Peptide-based cancer vaccines targeting immune suppression.

10.15-10.35

Karlijn van Loon
(Amsterdam, The Netherlands)

Translational development of a conjugate vaccine against the tumor vasculature.

10.35-10.45

Arjan Griffioen
(Amsterdam, The Netherlands)

Pan-cancer approach of multi-targeted conjugate vaccination.

10.45-11.30

Coffee/tea break

Session 2. Cancer vaccines II – chair: Else Huijbers (Amsterdam)

11.30-11.50

Monica Bequet
(Havana, Cuba)

HEBERSaVax: active targeting of human VEGF, the road so far

11.50-12.10

Michael Platten
(Heidelberg, Germany)

Targeting T cells to brain tumors

12.10-12.45

Olivera Finn
(Pittsburg, PA, USA)

Vaccines for the prevention of human non-viral cancers

12.45-13.05

Chris Meijer
(Amsterdam, The Netherlands)

Human Papilloma Virus infection: How to handle?

13.05-14.00

Lunch break – industry booths

International Meeting on Cancer Vaccines and Anti-Cancer Immunotherapy

Session 3. Cell-based therapy – chair: Tanja de Gruijl (Amsterdam)

14.00-14.20	Mirjam Heemskerk (Leiden, The Netherlands)	TCR therapy for hematological malignancies
14.20-14.40	Patrick Roth (Zurich, Switzerland)	Translational development of CAR T cell therapy for the treatment of glioblastoma.
14.40-15.00	Tassilo Wachsmann	Engineering dual-antigen specificity using a CAR and a TCR to prevent tumor escape

15.00-15.45 **Coffee/tea break**

Session 4. Immuno- and combination therapy – chair: Arjan Griffioen

15.45-16.05	Patrycja Nowak-Sliwinska (Geneva, Switzerland)	Patient-derived organoid-based development of combination therapy with targeted drugs.
16.05-16.25	Tanja de Gruijl (Amsterdam, The Netherlands)	Melanoma landscaping with oncolytic viruses.
16.25-16.45	Adriaan Bins (Amsterdam, The Netherlands)	Elongated frameshift peptide specific immunity in dMMR CRC patients treated with ICI and Ataluren - the ATAPEMBRO trial.
16.45-16.50	Closure – Arjan Griffioen	

16.50-18.00 **Drinks**